ReviewBiomedicines2018
The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction.
Review in Biomedicines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti-PD-1 Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Macrophages in Colorectal Cancer: from Normal Mucosa to Distant Metastasis: Beyond the M1/M2 Paradigm.Journal of Cancer · 2026Review
- Reengineered Anti-CD4 Cys-diabody Variants forMolecular imaging and biology · 2025Article
- Differential Mediating Roles of Immune-Inflammatory Cells in ≥HSIL Women: A Focus on HPV and CD4/CD8 or NLR.Journal of inflammation research · 2025Article
- Circulating free DNA as a predictive biomarker for response to nivolumab and platinum-based chemotherapy in metastatic esophageal adenocarcinoma: a prospective pilot study.Frontiers in oncology · 2025Article
- Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.Molecular carcinogenesis · 2024Article
- Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.Oncoimmunology · 2024Article
- Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.Frontiers in oncology · 2023Article
- Circular RNAs in peripheral blood mononuclear cells are more stable than linear RNAs upon sample processing delay.Journal of cellular and molecular medicine · 2022Article
- The potential of using blood circular RNA as liquid biopsy biomarker for human diseases.Protein & cell · 2021Review
- Regulation of ST6GAL1 sialyltransferase expression in cancer cells.Glycobiology · 2021Review
- Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.World journal of urology · 2021Review
- PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.Cancer immunology, immunotherapy : CII · 2021Article
- The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay.Biomedicines · 2021Article
- Polymer-loaded hydrogels serve as depots for lactate and mimic "cold" tumor microenvironments.Biomaterials science · 2020Article
- Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.Journal of translational medicine · 2020Article
- Prediagnostic Immune Cell Profiles and Breast Cancer.JAMA network open · 2020Article
- Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.Frontiers in immunology · 2020Review
- External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.International journal of clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional systemic and local immunity is required for effective anti-tumor responses. In addition to an active engagement with cancer cells and tumor stroma, immune cells can be affected and are often found to be dysregulated in cancer patients. The impact of tumors on local and systemic immunity can be assessed using a variety of approaches ranging from low-dimensional analyses that are performed on large patient cohorts to multi-dimensional assays that are technically and logistically challenging and are therefore confined to a limited sample size. Many of these strategies have been established in recent years leading to exciting findings. Not only were analyses of immune cells in tumor patients able to predict the clinical course of the disease and patients' survival, numerous studies also detected changes in the immune landscape that correlated with responses to novel immunotherapies. This review will provide an overview of established and novel tools for assessing immune cells in tumor patients and will discuss exemplary studies that utilized these techniques to predict patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.